Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2004

View Archived Issues

Preclinical antitumor activity of the novel Hsp90 inhibitor IPI-504

AV-201 enters phase I/II trial for Parkinson's disease

NIAID to test preventive SARS vaccine

Solvay seeks to acquire Neopharma

Accera establishes advisory boards to guide development efforts

Enrollment on track in ASSIST-2 study of Telcyta

NIAID approval for advanced preclinical testing of Mymetics' HIV vaccine

New liver safety information for Strattera

Proteome Systems to acquire Eukarion

MorphoSys and Schering AG extend collaboration

BMS and Gilead to develop fixed combination HIV medication

Allon files IND for phase I trial of AL-108 for Alzheimer's

Genaissance identifies markers implicated in clozapine-induced agranulocytosis

Cryptome to apply drug discovery platform to neuroinflammatory diseases

FTC does not oppose potential collaboration between Basilea and J&J

Three patents covering 5-HT4 receptor modulators filed by Dainippon

Ono discloses chemokine receptor ligands

New patent application covers antidiabetic agents

Two series of p38 MAP kinase inhibitors described in patent literature

AxyS (Celera Genomics) researchers prepare and test HDAC inhibitors for leukemia

Positive E.U. opinion for Pegasys combination therapy in HIV-HCV patients

Broad-spectrum caspase inhibitor blocks apoptosis in rodent model

Novel inhibitor of ABL tyrosine kinase more effective than imatinib in vivo

Remicade receives FDA approval for ankylosing spondylitis

Novel lipoxin analogue from Berlex promising for the treatment of IBD

Simvastatin plus chemotherapy induce antitumor response in end-stage myeloma or lymphoma

Cognitive improvements found with epoetin alfa in anemic patients with hematologic malignancies

FavId vaccine improves antitumor efficacy of rituximab in follicular lymphoma

Levoamphetamine reported to improve memory and cognition

Update on the efficacy of pregabalin in patients with partial seizures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...